Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Has chemotherapy anywhere to go?

T A Connors1

  • 1Toxicology Unit, Medical Research Council Laboratories, Carshalton, Surrey.

Cancer Surveys
|January 1, 1989
PubMed
Summary

Traditional anticancer agent detection methods need updating to focus on solid cancer treatments. New programs enable faster development, and sensitive tumor response markers could lead to discovering novel solid cancer drugs.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Combination chemotherapy.

Proceedings of the Royal Society of Medicine·2010
Same author

PDEPT: polymer-directed enzyme prodrug therapy. I. HPMA copolymer-cathepsin B and PK1 as a model combination.

British journal of cancer·2001
Same author

Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics.

British journal of cancer·1999
Same author

The development of anticancer agents.

The National medical journal of India·1998
Same author

Investigation of alternative prodrugs for use with E. coli nitroreductase in 'suicide gene' approaches to cancer therapy.

Gene therapy·1996
Same author

Bioreductive agents, hypoxic cells and therapy.

European journal of cancer (Oxford, England : 1990)·1996

Area of Science:

  • Oncology
  • Drug Discovery
  • Cancer Therapeutics

Background:

  • Current methods for detecting anticancer agents are insufficient for targeting common solid cancers.
  • There is a need for novel therapeutic strategies against solid tumors.

Purpose of the Study:

  • To advocate for the replacement of outdated detection methods with new approaches.
  • To highlight the potential of new chemical classes in treating solid cancers.
  • To emphasize the importance of developing sensitive markers for tumor response.

Main Methods:

  • Introduction of new programs for rapid preclinical development of chemical agents.
  • Focus on identifying and developing sensitive markers of tumor response.

Main Results:

  • New programs facilitate swift preclinical and clinical evaluation of novel chemical agents.
  • Development of sensitive markers is crucial for identifying effective treatments.

Conclusions:

  • Advancement in anticancer agent discovery requires a shift towards solid cancer-specific approaches.
  • Successful identification of novel anticancer agents hinges on developing robust tumor response markers.

Related Experiment Videos